Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Sexually Transmitted Infections01:26

Sexually Transmitted Infections

Sexually transmitted infections (STIs) are diseases transmitted primarily through unsafe sexual interactions. Bacteria, viruses, or parasites cause them and can result in severe health complications if untreated.ChlamydiaThe bacterium Chlamydia trachomatis is responsible for the disease Chlamydia, the most common STI in the United States. This peculiar pathogen requires human cells to reproduce, residing intracellularly. The initial infection often goes unnoticed because it typically does not...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disability pension and sick leave in people with HIV compared with the background population - a nationwide population-based matched cohort study.

AIDS (London, England)·2025
Same author

Risk of schizophrenia spectrum disorders among people with HIV: a nationwide, population-based, matched cohort study.

AIDS (London, England)·2025
Same author

No changes in weight, body composition or metabolic parameters after the switch to dolutegravir and lamivudine compared to continued treatment with dolutegravir, abacavir and lamivudine for virologically suppressed HIV infection (The AVERTAS trial).

BMC infectious diseases·2025
Same author

Risk of Cancer After Tuberculosis Disease Among People With HIV in Denmark: A Nationwide Population-Based Cohort Study.

The Journal of infectious diseases·2025
Same author

Pneumocystis Pneumonia-Is it Still a Threat Among People With Human Immunodeficiency Virus (HIV)? A Danish HIV Cohort Study.

Open forum infectious diseases·2025
Same author

Control of HIV across the WHO European region: progress and remaining challenges.

The Lancet regional health. Europe·2025
Same journal

Safety and efficacy of deltoid intramuscular long-acting cabotegravir and rilpivirine, a case series.

Antiviral therapy·2026
Same journal

Factors associated with immunological non-response in HIV patients receiving antiretroviral therapy in Southeast Asia: A systematic review.

Antiviral therapy·2026
Same journal

Epidemiology and clinical management of cytomegalovirus infection in transplant recipients in Central and Eastern Europe - a physician survey.

Antiviral therapy·2026
Same journal

It's about time: The association between abacavir and cardiovascular disease.

Antiviral therapy·2026
Same journal

Combination antiviral and anti-CMV immunoglobulin therapy for CMV infection: A case-control study.

Antiviral therapy·2026
Same journal

Harnessing SuperNatural database to identify VP35 inhibitors as anti-Ebola drug candidates: A multistage <i>In silico</i> study.

Antiviral therapy·2025
See all related articles

Related Experiment Video

Updated: Jun 13, 2026

Comprehensive &amp; Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

Earlier testing for HIV--how do we prevent late presentation?

Yazdan Yazdanpanah1, Joep Lange, Jan Gerstoft

  • 1Service Universitaire des Maladies Infectieuses et du Voyageur, Centre Hospitalier de Tourcoing, Tourcoing, France. yyazdan@yahoo.com

Antiviral Therapy
|May 6, 2010
PubMed
Summary
This summary is machine-generated.

Late diagnosis of human immunodeficiency virus (HIV) is a challenge across Europe. Implementing routine provider-initiated HIV testing in high-risk settings and healthcare facilities can improve early identification and treatment.

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Related Experiment Videos

Last Updated: Jun 13, 2026

Comprehensive &amp; Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Area of Science:

  • Public Health
  • Infectious Diseases
  • Epidemiology

Background:

  • HIV testing policies and practices exhibit significant variation throughout Europe.
  • Late presentation for human immunodeficiency virus (HIV) diagnosis and care occurs across diverse risk groups and healthcare settings.
  • Earlier identification and treatment of late-presenting HIV patients are crucial for improved outcomes.

Purpose of the Study:

  • To explore strategies for earlier identification and treatment of late-presenting HIV patients.
  • To review current HIV testing policies and practices in Europe.
  • To highlight the need for enhanced HIV screening protocols.

Main Methods:

  • Review of existing literature and European HIV testing policies.
  • Analysis of potential strategies for routine HIV testing.
  • Consideration of rapid testing technologies and barriers to testing.

Main Results:

  • Routine provider-initiated HIV testing in at-risk groups (e.g., STI clinics, drug programs, antenatal care) is a viable strategy.
  • Routine HIV testing in healthcare facilities, including emergency and primary care, may be beneficial in areas with elevated HIV prevalence.
  • Leveraging rapid testing technologies and addressing community-specific barriers can increase testing uptake.

Conclusions:

  • Implementing targeted and routine HIV testing strategies can lead to earlier diagnosis and treatment.
  • Healthcare providers should consider universal or risk-based HIV testing approaches.
  • Addressing barriers and utilizing rapid testing are key to improving HIV case finding in Europe.